Study of chemotherapy plus ivonescimab for first-line advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of platinum chemotherapy, a paclitaxel nanoparticle formulation, and ivonescimab (an immunotherapy) as the first treatment for people with advanced squamous non-small cell lung cancer that has spread or come back. The goal is to see if this combination helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called squamous non-small cell lung cancer that has spread or come back and cannot be removed by surgery.
- You have not had any previous chemotherapy or immunotherapy for advanced disease.
- You are 18 years or older and able to give informed consent.
- You have at least one tumor that can be measured on scans.
- Your liver, kidney, and blood cell counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This study tests a combination of two experimental drugs (EVM14 and ivonescimab) in patients with advanced squamous cell lung cancer that cannot be cured with surgery or radiation alone. The drugs work by helping your immune system fight cancer cells.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
This Phase 3 trial tests ivonescimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). It may help people by improving how well the cancer responds, especially in tumors with PD-L1 activity, but you must meet specific medical and testing requirements.
Hear when a new Squamous Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.